Patients now have the choice of two different automated insulin delivery (AID) systems for the treatment of T2D after the results of a control group study published in NEJM on March 19, 2025, further demonstrated the benefits of AID systems in treating T2D.

Kevin Willmann

In April 2025, FDA issued an alert to health care providers, compounders, and consumers about potential risks associated with compounded topical finasteride products. The alert was issued after FDA was made aware of adverse events involving these products, which are not FDA-approved.

Lauren Howell, PharmD

Sulfonylureas are high risk for older adults due to the possibility of hypoglycemia. A clinical pharmacist intervention achieved a 41% deprescribing rate of sulfonylureas in older adult patients in a managed care setting, according to study results published March 15, 2025, in JAPhA.

Jen Hand

GLP-1 receptor agonists like semaglutide (Ozempic) have transformed the management of T2D and obesity. However, their increasing use has introduced new challenges in other areas of clinical care, including GI procedures.

Sonya Collins

Camu camu supplements are touted as a potent immune boost, supporting overall wellness and skin health.

Mickie Cathers